Abstract:

Objective To investigate the relationships of prognosis of schizophrenic patients with their serum prolactin （PRL）， glial fibrillary acid protein （GFAP）. Methods A total of 128 schizophrenic patients admitted to the hospital from January 2020 to January 2022 were admitted and treated with risperidone in our hospital. The prognostic status of the patients after 12 months of treatment was analyzed， the prognostic factors were explored and the prognostic value of PRL and GFAP were investigated. Results Forty-one patients had poor prognoses. By Logistic multivariate regression analysis， the prognostic factors in the schizophrenic patients were found to include brain-derived neurotrophic factor （BDNF） （OR = 3.931， 95%CI： 1.618 ~ 9.555）， nerve growth factor （NGF） （OR = 3.861， 95%CI：1.589 ~ 9.384）， PRL （OR = 3.666， 95%CI： 1.508 ~ 8.909） and GFAP （OR = 4.297， 95%CI： 1.768 ~ 10.444） were （P < 0.05）. By receiver operating characteristic （ROC） curve analysis， the sensitivities of PRL， GFAP and their combination in predicting the prognoses of the patients were 70.73% （95%CI： 54.26% ~ 83.35%）， 73.17% （95%CI： 56.79% ~ 85.25%）， and 80.49% （95%CI： 64.63% ~ 90.63%）， respectively； the specificities were 75.86% （95%CI： 65.28% ~ 84.12%）， 73.56% （95%CI： 62.83% ~ 82.18%）， and 87.36% （95%CI： 78.09% ~ 93.22%）， respectively； and the AUCs were 0.743 （95%CI： 0.643 ~ 0.843）， 0.739 （95%CI： 0.633 ~ 0.845） and 0.884 （95%CI： 0.816 ~ 0.952）， respectively. Conclusion PRL combined with GFAP is effective in predicting the prognoses of patients with schizophrenia.

Key words: schizophrenia, prolactin, glial fibrillary acidic protein, prognosis